Big news for MDMA-assisted therapy. Here are a couple takes on it:
https://themicrodose.substack.com/p/breaking-news-federal-regulators
https://psychedelicinvest.com/fda-denies-lykos-and-requests-another-trial/
PSYCHOTHERAPY FOR ADOLESCENTS, CHildren AND ADULTS
Big news for MDMA-assisted therapy. Here are a couple takes on it:
https://themicrodose.substack.com/p/breaking-news-federal-regulators
https://psychedelicinvest.com/fda-denies-lykos-and-requests-another-trial/
The Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee voted overwhelmingly to reject MDMA-assisted therapy in the treatment of post traumatic stress disorder, or PTSD.
The FDA will issue its final decision on the matter in mid-August but in the majority of cases, the federal agency’s decisions align with the vote of the independent panelists on advisory committees.
Read moreTwo articles cover this recent update.
npr: Misconduct claims may derail MDMA psychedelic treatment for PTSD
Axios: Landmark review spotlights challenge of judging psychedelic therapies
Read moreResearch suggests that the psychedelic drug MDMA, an empathogenic stimulant also known as Molly or ecstasy, can spark changes in the brain that induce a childlike state of neuroplasticity and help forge new neural connections.
(It could well be approved for PTSD by the U.S. Food and Drugs Administration in August after two advanced stage trials showed significant benefits.)
Researchers are also studying other psychedelics as well, like the powerful drug ibogaine.
Read moreMDMA therapy for PTSD could become a new treatment option for millions of people living with trauma. The clinical evidence is growing.
Read moreFuture clinical trials should determine whether psychedelic-assisted therapy holds promise for individuals with complex trauma and alcohol misuse who have not been successfully treated with traditional interventions.
Read moreHere’s the official statement from MAPS!
The results confirmed findings from MAPP1; no serious adverse events were observed among the participants
In a first for psychedelic-assisted therapy trials, more than half of MAPP2 participants identify as people of color
Veterans are turning to psychedelic treatments for PTSD healing.
Read moreGreat news! The first Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) replicated and expanded on Phase 2 results indicating MDMA-assisted therapy may be an effective and cost-saving treatment for PTSD resulting from any cause.
Read moreA ‘magic mushroom’ nasal spray has been designed to make microdosing easier for people trying to treat PTSD or depression. An Oregon company has developed a magic mushroom nasal spray in Jamaica – where psilocybin is legal – for controlled, metered-dosing known as ‘microdosing’.
Read moreAs a first responder, Nick Watchorn had seen many terrible things in the course of his career. But the massive shooting of April 28, 1986 in Tanzania, Australia, completely shook his handle on reality. Now Nick is part of the experimental studies on therapeutic MDMA or PTSD treatment.
Read more